However, apatinib and axitinib, small‐molecule inhibitors targeting VEGFR, are potentially effective for ACC in a series of small‐sample clinical studies, though their efficacy still needs to be confirmed in subsequent trials [19, 20]. The gene discussed is KDR; the disease is adrenal cortex carcinoma.